Eli Lilly’s decision to start selling a new version of its most popular fast-acting insulin highlights the industry’s concerns about possible legislation or regulation to rein in drug prices. Reality check: Some diabetic patients will benefit from Lilly’s new authorized generic, called Lispro. But the PR-heavy move, which has been replicated for other controversially priced medicines, isn’t structural change. It aligns with the Trump administration’s goal...